How to create incentives for the development of novel antibiotics?
Panel discussion as part of the World Health Summit 2023
Every year at least 700,000 people die as a result of infection with antibiotic-resistant bacteria—a figure which according to WHO forecasts could rise to ten million people by 2050 without new measures to combat the development and spread of resistance. "We need market-based incentives to encourage the development of new, resistance-breaking antibiotics," was the unanimous opinion of the experts on the panel at the World Health Summit (WHS) on 16 October 2023. The German Network against Antimicrobial Resistance (DNAMR), of which the German Center for Infection Research is also a member, made its first joint appearance at the WHS with this event and also hosted the only workshop on the topic of antibiotic resistance.
Organised by DNAMR, the panel discussed how to create market-based incentives for the development of new, resistance-breaking antibiotics in order not to lose the race against increasing resistance. Prof. Mathias W. Pletz, Director of the Institute of Infectious Diseases and Infection Control at the Friedrich Schiller University in Jena, Germany, introduced the topic to the audience.
The video of the event and the slides can be viewed and downloaded below:
Video of the event
Click on the arrow to start the video. Active content from YouTube is only loaded and personal data is only transferred to YouTube when this video is called up; more information in our privacy policy.
Slides from the panellists (PDF)
- Joël Denis (Director General of the Public Health Agency Canada, Centre for Vaccine and Therapeutics Readiness)
- Dr Lesley Ogilvie (Director at the Global AMR R&D Hub Secretariat)
- Marc Gitzinger (President of the Board of the Beam Alliance, CEO and founder at BioVersys AG)
- Prof. Kevin Outterson (Executive Director at CARB-X)
Source: News from the German Network against Antimicrobial Resistance (German only)
